A large, international study published in Cell has found that the collection of bacteria in a person’s gut can predict whether high‑risk melanoma (skin cancer) will return after surgery and immunotherapy.
The analysis, drawn from a global clinical trial, shows that specific bacterial groups in stool samples forecast recurrence with striking accuracy when patients are compared according to the overall pattern of their gut microbiome.
The findings point to a practical new way to identify patients most likely to benefit from closer monitoring or altered treatment plans and hint at future microbiome‑guided cancer care.
Melanoma is the most dangerous form of skin cancer, arising from pigment-producing cells (melanocytes) usually due to excessive UV exposure. Symptoms include new, expanding, or changing moles, often irregular in shape and color. Early detection is critical, as it can spread quickly, but it is highly curable in early stages.
Melanoma recurrence remains a pressing clinical problem. Even after complete surgical removal of primary tumours and treatment with modern immune checkpoint inhibitors, a substantial proportion of patients—historical estimates range from about 25% to 40%—experience a return of disease.
Predicting which patients will relapse has proved difficult. Traditional clinical and pathological features give some guidance but lack the precision needed to personalise follow‑up and additional therapy.
The new study offers a different kind of biomarker — the gut microbiome.
Researchers analysed stool samples collected from 674 patients enrolled in a large, international trial of adjuvant immunotherapy following resection of high‑risk melanoma.
The trial compared two regimens: a dual immune checkpoint blockade and a single‑agent approach. Patients came from multiple parts of the world, including North America, Western Europe, Eastern Europe, Australia and other regions. Investigators used high‑throughput sequencing to read the DNA of the microbes present in each sample, producing a full catalogue of species and their relative abundances. They then asked whether patterns in those catalogues were associated with recurrence‑free survival during the follow‑up period.
“Predictive performance varied by region, with accuracy estimates ranging from about 83% to 94%. In practical terms, a pre‑treatment stool test could, after comparison with a suitable reference database, provide a reliable forecast of recurrence risk for many patients”
Two key themes emerged. First, certain bacterial taxa were strongly associated with the risk of melanoma recurrence. Taxa most closely linked to changes in recurrence risk included members of the groups Eubacterium, Ruminococcus, Firmicutes and Clostridium. These bacterial groups are already known to interact with the immune system in ways that can influence tumour biology and response to immune therapies. They can affect immune cell activation, modulate inflammation, and alter the availability of nutrients such as sugars that tumours can exploit.
Second, geography mattered. The bacterial markers that predicted recurrence most accurately differed depending on where patients lived. Earlier studies had reported inconsistent findings across cohorts from different countries, producing confusion about whether the microbiome could ever provide a reliable, generalisable biomarker.
This new analysis resolves that tension with a clever approach, instead of assuming a single, universal microbial signature, the investigators first matched patients on the overall similarity of their gut microbiomes.
In other words, they grouped patients who shared a common microbiome “fingerprint” regardless of national borders. Within these matched groups, they identified the bacterial species whose presence or absence tracked with subsequent relapse.
This matching strategy produced impressive results. When patients were compared against others with similar microbiome backgrounds, signatures derived from one region were able to predict recurrence in patients from different regions, but only if those patients shared a similar overall microbial fingerprint.
“Specific bacterial taxa can interact with immune cells such as natural killer cells and T lymphocytes, altering immune surveillance and the efficacy of immunotherapies. Some bacteria produce metabolites that feed or starve tumour cells. Others modulate the tumour microenvironment through inflammatory mediators”
Predictive performance varied by region, with accuracy estimates ranging from about 83% to 94%. In practical terms, a pre‑treatment stool test could, after comparison with a suitable reference database, provide a reliable forecast of recurrence risk for many patients.
The study adds nuance to the debate about microbiome biomarkers. On one hand, the gut microbiome is not uniform. Diet, environment, genetics, medication use and many other factors shape a person’s microbial community.
These influences create population‑level differences that can confound attempts to identify a single “good” or “bad” microbiome. On the other hand, the investigators show that those differences need not be an insurmountable obstacle. By accounting for a patient’s overall microbiome context, it becomes possible to extract meaningful, clinically relevant signals that generalise beyond a single country or cohort.
Findings like these rest on plausible biology. Specific bacterial taxa can interact with immune cells such as natural killer cells and T lymphocytes, altering immune surveillance and the efficacy of immunotherapies. Some bacteria produce metabolites that feed or starve tumour cells. Others modulate the tumour microenvironment through inflammatory mediators. The taxa highlighted in the analysis have been implicated in these processes in previous research, giving biological credibility to their association with recurrence risk.
“Clinical implications are immediate and practical. For patients at high risk of relapse, knowing their microbiome‑based prognosis before or at the start of adjuvant therapy could inform multiple decisions”
The research team also examined stability. They observed that the gut microbiome remained remarkably stable in patients during the year‑long course of immunotherapy. This stability matters because it implies that a single baseline test, taken before treatment begins, may be sufficient to forecast recurrence risk. A one‑time stool sample is far easier to implement in routine care than repeated measurements. It also reduces the burden on patients and the healthcare system.
Clinical implications are immediate and practical. For patients at high risk of relapse, knowing their microbiome‑based prognosis before or at the start of adjuvant therapy could inform multiple decisions.
Physicians might recommend closer surveillance for those judged at higher risk, intensify adjuvant treatment, or prioritise enrolment in trials of novel therapeutic combinations. Patients deemed at lower risk could avoid unnecessary additional treatments and the associated toxicities. Over time, microbiome profiling could join imaging, histopathology and molecular tumour markers as part of an integrated framework for personalised oncology.
Important caveats remain. The method depends on matching a patient to an appropriate reference group with a similar microbiome. That requirement underscores the need for large, diverse databases that represent the global breadth of human gut microbiomes.
Many microbiome studies to date have sampled predominantly from high‑income countries, limiting the diversity of reference populations. To achieve equitable clinical application, researchers will need to build expansive, multi‑ethnic, multi‑regional repositories of microbiome data. Without that investment, the predictive method risks underperforming in under‑represented populations.
Moreover, association is not causation. The presence of particular bacteria need not be the direct cause of recurrence risk; they may act as markers of other exposures or host factors that influence outcomes. Interventional studies will be necessary to test whether manipulating the gut microbiome—through diet, probiotics, antibiotics, faecal microbiota transplantation or other means—can alter recurrence risk or enhance the effects of immunotherapy.
Those trials are complex. They must account for individual variability in microbiome ecology and the possibility that altering one component of the system has unpredictable ripple effects.
The study’s design offers safeguards against common pitfalls. Large sample size, international representation and robust sequencing methods strengthen the credibility of the findings. The matching approach addresses heterogeneity across regions. The observation of microbiome stability through treatment reduces concerns that immunotherapy itself is the major driver of the microbial differences observed.
Yet replication remains essential. Independent confirmation in other cancer types and in additional melanoma cohorts will help define the method’s limits and generalisability.
Looking ahead, the investigators envision practical workflows that could be integrated into clinical practice. A patient’s pre‑treatment stool sample could be sequenced and compared with a global database to identify the nearest microbial matches. An algorithm would then estimate recurrence risk based on the presence or absence of key taxa within that matched context.
In the broader picture, the study exemplifies a shift in cancer research. Increasingly, scientists are looking beyond tumour genetics to host factors—immune system traits, metabolism, and now the microbiome—that influence treatment outcomes.
The human microbiome is not a curious sideline. It is a major determinant of health and disease. Harnessing it for prognostic and therapeutic purposes requires careful science, diverse datasets and thoughtful clinical translation.
For clinicians and patients, the message is cautiously optimistic. A single pre‑treatment stool test may soon provide useful prognostic information for patients with high‑risk melanoma undergoing adjuvant immunotherapy. Predictive accuracy appears high when patients are matched to comparable microbiome profiles.
The approach could reduce uncertainty, personalise follow‑up, and point to new interventional strategies.
The post The Gut Bacteria Types Could Predict Melanoma Recurrence at High Accuracy first appeared on PP Health Malaysia.
